In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.
The study, led by TSRI Associate Professor Susana Valente, was published online Oct. 17 before print in the journal Cell Reports.
“No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo,” Valente said. “When combining this drug with the standard cocktail of anti-retrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present—it is really the proof-of-concept for a ‘functional cure.’”
Valente, a pioneer in this new approach, calls it “Block-and-Lock”—the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.
Valente and her colleagues use a derivative of a natural compound called didehydro-Cortistatin A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral transcriptional activator, called Tat, halting viral production, reactivation and replenishment of the latent viral reservoir.
“Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation,” Valente said. “It’s important to note that our study uses the maximum tolerable dose of the drug—with virtually no side effects.”
The scientists studied the combination therapy in a mouse model of HIV latency and persistence. Once the combined treatment regimen was halted, viral rebound was delayed up to 19 days, compared with just seven days in mouse models receiving only anti-retroviral treatment.
“This demonstrates the potential of ‘block-and-lock’ strategies,” said TSRI Research Associate Cari F. Kessing, co-first author of the study. “This study shows that a ‘functional cure’ approach can succeed in reducing residual virus in the blood during anti-retroviral treatment and limiting viral rebound during treatment interruption.”
“In half of the dCA treated mice, the virus was undetectable for 16 days after all treatment was halted,” said the University of North Carolina’s Christopher Nixon, another first author.
“We blocked Tat, and the cell’s machinery did the rest,” said TSRI Research Associate Chuan Li, a coauthor of the study. “The result was that the HIV promoter becomes repressed.”
Valente pointed out that the animal models were exposed to just a single month of treatment. “That’s a relatively short period of time,” she said. “We think longer treatments will result in longer, or even permanent, rebound delays. The question is how long? We’re studying that now.”
Because any viral rebound of HIV comes with a host of adverse effects, Valente noted, blocking that rebound would automatically reduce those effects.
“This is the only class of drugs that stops infected cells from making viruses outright,” said Valente. “All current antivirals work later in the viral lifecycle, so only a HIV transcriptional inhibitor like dCA can stop the side effects of low-level virus production.”
Learn more: New Research Opens the Door to ‘Functional Cure’ for HIV
The Latest on: HIV
[google_news title=”” keyword=”HIV” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]- Animal studies lend support to an innovative HIV vaccine strategy — but there’s still a long way to goon May 17, 2024 at 10:51 am
Studies in mice and monkeys showed that immune cells could be shepherded to produce antibodies that block a broad swath of HIV strains — a first step toward a potential vaccine.
- There’s New Hope for an HIV Vaccineon May 17, 2024 at 10:19 am
A trial vaccine has succeeded in generating low levels of antibodies needed to target HIV. It’s a first but much-needed step toward preventing infection.
- Major breakthrough in search for HIV vaccine that could save millions of liveson May 17, 2024 at 9:03 am
A vaccine for HIV is a massive step closer following trials in the US in which a test jab triggered antibodies capable of neutralising the virus. The immune response happened within weeks of a ...
- Trial HIV vaccine triggers elusive and essential antibodies, pointing the way toward a successful vaccineon May 17, 2024 at 8:00 am
An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 ...
- Major breakthrough in search for HIV vaccine that could save millionson May 17, 2024 at 8:00 am
HIV, or human immunodeficiency virus, damages cells in the immune system, weakening the body’s ability to fight normal infections and disease. It can now be well managed using medication, but is still ...
- UNIFIED HIV Services Gets a Power-Up With New Vivent Health Mergeron May 17, 2024 at 6:44 am
Southeast Michiganders have relied on UNIFIED HIV Health and Beyond for a wealth of resources, from pop-up, confidential testing ...
- Gilead Sciences brings on Omnicom to handle HIV portfolioon May 16, 2024 at 5:00 pm
Biopharmaceutical company Gilead Sciences is bringing on Omnicom Group to manage PR for its HIV portfolio, according to a source familiar with the matter. A Gilead spokesperson declined to comment on ...
- Pelosi HIV money doesn't necessarily fix SF's federal funding shortfallon May 16, 2024 at 3:53 pm
Though Congressmember Nancy Pelosi announced $1.6 million in new federal funding for San Francisco from the Ryan White HIV/AIDS Program to reduce infections, that doesn’t mean the city isn’t still ...
- 4 Critical Biometrics EVERY Black HIV Patient Should Knowon May 16, 2024 at 12:08 pm
If you’re managing your HIV/AIDS, here are four aspects/biometrics of your health you absolutely need to keep an eye ...
- Global HIV Antivirals Market Soars to Projected to Reach USD 47.0 Billion by 2032on May 15, 2024 at 6:13 pm
HIV Antivirals Market poised to achieve an estimated value of USD 47.0 billion by the conclusion of 2032 a steady CAGR of 4.4%.
via Google News and Bing News